Skip to main content

Table 1 Demographics, plasma biomarkers and clinical variables

From: Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients

 

Non-progression to AD dementia (n = 84)

Progression to AD dementia (n = 26)

p-value

Age, years

71.52 ± 8.20

74.77 ± 8.12

0.08

Sex F to M (%)

38:46 (45%)

14:12 (54%)

0.59

Years of education

13.62 ± 4.01

14.42 ± 3.81

0.36

APOE4 carriers: non carriers (%)a

21:56 (27%)

14:9 (61%)

0.006

Plasma p-tau217, pg/ml

0.25 ± 0.24

0.62 ± 0.36

< 0.001

Plasma NfL, pg/ml

13.94 ± 6.99

19.14 ± 6.77

0.002

Plasma Aβ42/Aβ40b

0.06 ± 0.01

0.05 ± 0.01

0.13

Plasma GFAPb, pg/ml

164.69 ± 117.31

251.30 ± 115.21

0.006

Hippocampal volume, cm3

4.72 ± 0.72

4.41 ± 0.68

< 0.001

mPACC

0.15 ± 0.82

− 0.50 ± 0.82

0.001

  1. Data are presented as mean ± standard deviation unless specified otherwise. p-values were obtained from t-test or chi-square (sex and APOE4) comparing the two MCI groups, i.e., those who progressed to AD dementia within three years vs. those who did not
  2. Abbreviations Aβ beta-amyloid, APOE4 apolipoprotein E genotype (carrying at least one ε4 allele), GFAP glial fibrillary acidic protein, mPACC modified Preclinical Alzheimer’s Cognitive Composite, NfL neurofilament light, p-tau217 phosphorylated tau 217
  3. a Genotype missing for 7 non progressors and 3 progressors
  4. b Values available for 80/110 participants (59 non-progressors and 21 progressors)